Novan News, Novan Quote, NOVN Quote

Novan (NQ:NOVN) Delayed: 0.09 --0 (-0%)

Prev. Close

$0.09

Open

$0.09

52 Wk High

$23.79

52 Wk Low

$13.73

Day High

$0.09

Day Low

$0.09

P/E

0.09

EPS

$1.05

Volume

1,273,099

Friends, Peers and Foes (?): NVS, LGND, CL, LCO, GC (more...)

Apr 23, 2024 06:07 AM Form 6-K NOVARTIS AG For: Mar 31
Apr 17, 2024 01:31 AM Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
Apr 11, 2024 07:00 AM Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Trea
Feb 25, 2024 02:00 PM New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies
Feb 20, 2024 08:10 AM Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis
Feb 16, 2024 11:21 AM FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies
Feb 15, 2024 04:16 PM Form S-8 POS NOVARTIS AG
Feb 2, 2024 02:19 PM Form SC 13G/A NOVARTIS AG Filed by: BlackRock Inc.
Jan 31, 2024 07:45 AM Form 6-K NOVARTIS AG For: Dec 31
Jan 31, 2024 07:44 AM Form 6-K NOVARTIS AG For: Dec 31

Entities mentioned with NOVN